March 2021 FDA Recall Drug by Sun Pharmaceutical Industries Inc
D-0320-2021 - Failed Impurities/Degradation Specifications

This Class II drug recall was voluntarily initiated by Sun Pharmaceutical Industries Inc on March 15, 2021 for the product Drug. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed in NJ and the recall is currently terminated.

Recall Number: D-0320-2021

Reason for Recall
Failed Impurities/Degradation Specifications
Initiated
03-15-2021
Reported
04-14-2021
Quantity
91,211 syringes

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
SUN PHARMACEUTICAL INDUSTRIES INC
Ganirelix Acetate Injection, 250 mcg/0.5 mL, Sterile Prefilled Syringe, Rx only, Distributor: Ferring Pharmaceuticals, Inc., Parsippany, NJ 07054 USA, Manufactured by: Sun Pharmaceutical Industries Ltd, Halol, Gujarat, India Made in India, NDC 55566-1000-1.

Batch or Lot Expiration Information

Lot# Lots JKU1212A, JKU1503A, JKU1504A, JKU1505A, JKU1506A, Exp 03/2021; JKU3313A & JKU3314A, Exp 08/2021.